These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

545 related articles for article (PubMed ID: 34011405)

  • 41. Oncostatin M (OSM) cytostasis of breast tumor cells: characterization of an OSM receptor beta-specific kernel.
    Underhill-Day N; Heath JK
    Cancer Res; 2006 Nov; 66(22):10891-901. PubMed ID: 17108126
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma.
    Wong CC; Tse AP; Huang YP; Zhu YT; Chiu DK; Lai RK; Au SL; Kai AK; Lee JM; Wei LL; Tsang FH; Lo RC; Shi J; Zheng YP; Wong CM; Ng IO
    Hepatology; 2014 Nov; 60(5):1645-58. PubMed ID: 25048396
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The AB loop of oncostatin M (OSM) determines species-specific signaling in humans and mice.
    Adrian-Segarra JM; Sreenivasan K; Gajawada P; Lörchner H; Braun T; Pöling J
    J Biol Chem; 2018 Dec; 293(52):20181-20199. PubMed ID: 30373773
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dormant tumor cells expressing LOXL2 acquire a stem-like phenotype mediating their transition to proliferative growth.
    Weidenfeld K; Schif-Zuck S; Abu-Tayeh H; Kang K; Kessler O; Weissmann M; Neufeld G; Barkan D
    Oncotarget; 2016 Nov; 7(44):71362-71377. PubMed ID: 27655685
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The pathological significance of LOXL2 in pre-metastatic niche formation of HCC and its related molecular mechanism.
    Wu S; Xing X; Wang Y; Zhang X; Li M; Wang M; Wang Z; Chen J; Gao D; Zhao Y; Chen R; Ren Z; Zhang K; Cui J
    Eur J Cancer; 2021 Apr; 147():63-73. PubMed ID: 33618200
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Specific protein 1(SP1) regulates the epithelial-mesenchymal transition via lysyl oxidase-like 2(LOXL2) in pancreatic ductal adenocarcinoma.
    Kim IK; Lee YS; Kim HS; Dong SM; Park JS; Yoon DS
    Sci Rep; 2019 Apr; 9(1):5933. PubMed ID: 30976063
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lysyl oxidase-like 2 promotes migration in noninvasive breast cancer cells but not in normal breast epithelial cells.
    Hollosi P; Yakushiji JK; Fong KS; Csiszar K; Fong SF
    Int J Cancer; 2009 Jul; 125(2):318-27. PubMed ID: 19330836
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor Cell Invasion Can Be Blocked by Modulators of Collagen Fibril Alignment That Control Assembly of the Extracellular Matrix.
    Grossman M; Ben-Chetrit N; Zhuravlev A; Afik R; Bassat E; Solomonov I; Yarden Y; Sagi I
    Cancer Res; 2016 Jul; 76(14):4249-58. PubMed ID: 27221706
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Human lysyl oxidase-like 2.
    Moon HJ; Finney J; Ronnebaum T; Mure M
    Bioorg Chem; 2014 Dec; 57():231-241. PubMed ID: 25146937
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lysyl oxidase-like 2 is a regulator of angiogenesis through modulation of endothelial-to-mesenchymal transition.
    de Jong OG; van der Waals LM; Kools FRW; Verhaar MC; van Balkom BWM
    J Cell Physiol; 2019 Jul; 234(7):10260-10269. PubMed ID: 30387148
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Loss of oncostatin M receptor beta in metastatic melanoma cells.
    Lacreusette A; Nguyen JM; Pandolfino MC; Khammari A; Dreno B; Jacques Y; Godard A; Blanchard F
    Oncogene; 2007 Feb; 26(6):881-92. PubMed ID: 16909117
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Role of oncostatin-M in ECM remodeling and plaque vulnerability.
    Patel P; Rai V; Agrawal DK
    Mol Cell Biochem; 2023 Nov; 478(11):2451-2460. PubMed ID: 36856919
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling.
    Junk DJ; Bryson BL; Smigiel JM; Parameswaran N; Bartel CA; Jackson MW
    Oncogene; 2017 Jul; 36(28):4001-4013. PubMed ID: 28288136
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Oncostatin M modulates fibroblast function via signal transducers and activators of transcription proteins-3.
    Nagahama KY; Togo S; Holz O; Magnussen H; Liu X; Seyama K; Takahashi K; Rennard SI
    Am J Respir Cell Mol Biol; 2013 Oct; 49(4):582-91. PubMed ID: 23668543
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Emerging role of LOXL2 in the promotion of pancreas cancer metastasis.
    Park JS; Lee JH; Lee YS; Kim JK; Dong SM; Yoon DS
    Oncotarget; 2016 Jul; 7(27):42539-42552. PubMed ID: 27285767
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oncostatin M sensitizes keratinocytes to UVB-induced inflammation via GSDME-mediated pyroptosis.
    Liu J; Zhong Y; Liu H; Yang H; Lu P; Shi Y; Wang X; Zheng W; Yu X; Xu Y; Yang B
    J Dermatol Sci; 2021 Nov; 104(2):95-103. PubMed ID: 34674925
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Silencing of lysyl oxidase‑like 2 inhibits the migration, invasion and epithelial‑to‑mesenchymal transition of renal cell carcinoma cells through the Src/FAK signaling pathway.
    Hong X; Yu JJ
    Int J Oncol; 2019 May; 54(5):1676-1690. PubMed ID: 30816490
    [TBL] [Abstract][Full Text] [Related]  

  • 58. M2 polarization of macrophages by Oncostatin M in hypoxic tumor microenvironment is mediated by mTORC2 and promotes tumor growth and metastasis.
    Shrivastava R; Asif M; Singh V; Dubey P; Ahmad Malik S; Lone MU; Tewari BN; Baghel KS; Pal S; Nagar GK; Chattopadhyay N; Bhadauria S
    Cytokine; 2019 Jun; 118():130-143. PubMed ID: 29625858
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Oncostatin M promotes STAT3 activation, VEGF production, and invasion in osteosarcoma cell lines.
    Fossey SL; Bear MD; Kisseberth WC; Pennell M; London CA
    BMC Cancer; 2011 Apr; 11():125. PubMed ID: 21481226
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer.
    Doherty MR; Parvani JG; Tamagno I; Junk DJ; Bryson BL; Cheon HJ; Stark GR; Jackson MW
    Breast Cancer Res; 2019 Apr; 21(1):54. PubMed ID: 31036052
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.